Genetic Disorder News and Research

RSS
Jain Foundation's dysferlinopathy clinical study exceeds original goal of 150 patients

Jain Foundation's dysferlinopathy clinical study exceeds original goal of 150 patients

Researcher honored with Pfizer/ACMG Foundation Translational Genomic Scholars Fellowship Award at ACMG

Researcher honored with Pfizer/ACMG Foundation Translational Genomic Scholars Fellowship Award at ACMG

Researchers find potential way to ease physical damage of numerous genetic disorders

Researchers find potential way to ease physical damage of numerous genetic disorders

Machaon Diagnostics' aHUS Genetic Panel confirms atypical Hemolytic Uremic Syndrome in 48 hours

Machaon Diagnostics' aHUS Genetic Panel confirms atypical Hemolytic Uremic Syndrome in 48 hours

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

New gene-editing system holds potential for treating many genetic disorders

New gene-editing system holds potential for treating many genetic disorders

Research findings help explain rare genetic disorder that causes immunodeficiency syndrome

Research findings help explain rare genetic disorder that causes immunodeficiency syndrome

Study lays groundwork for PET imaging studies on human Menkes disease

Study lays groundwork for PET imaging studies on human Menkes disease

New way to make large concentrations of skeletal muscle cells from human stem cells

New way to make large concentrations of skeletal muscle cells from human stem cells

Researchers identify steps by which cell removes RNA from cytoplasm

Researchers identify steps by which cell removes RNA from cytoplasm

New tool pinpoints genetic sources of disease

New tool pinpoints genetic sources of disease

USTAR Center for Genetic Discovery to integrate genome data with patient care

USTAR Center for Genetic Discovery to integrate genome data with patient care

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Patients with congenital disorders are urged to register with CMDIR to advance clinical trials

Patients with congenital disorders are urged to register with CMDIR to advance clinical trials

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

Trophos' olesoxime shows beneficial effect on maintaining motor function in SMA patients

Trophos' olesoxime shows beneficial effect on maintaining motor function in SMA patients

Scientists throw light on genetic mutation that causes particularly severe genetic disease ARVC5

Scientists throw light on genetic mutation that causes particularly severe genetic disease ARVC5

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Scientists throw light on genetic mutation that causes ARVC5 in Newfoundland

Scientists throw light on genetic mutation that causes ARVC5 in Newfoundland

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.